<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bovine heart <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> specifically inhibits platelet aggregation induced by PAF in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>In the past we have reported that patients with primary <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo> have increased PAF levels in plasma (Iatrou et al., 1995b) </plain></SENT>
<SENT sid="2" pm="."><plain>In this work we investigate the existence of <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> in the blood of end-stage renal patients due to primary <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo> and we study its implication in the biological study of PAF </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="23" ids="18059">Lipids</z:chebi> from blood samples of end-stage renal patients were extracted, fractionated onto <z:chebi fb="2" ids="26675">silicic acid</z:chebi> column and onto High Performance Liquid Chromatography (HPLC) <z:chebi fb="36" ids="36916">cation</z:chebi> exchange column </plain></SENT>
<SENT sid="4" pm="."><plain>PAF fraction was removed and <z:chebi fb="1" ids="16247">phospholipids</z:chebi> were separated from the rest <z:chebi fb="23" ids="18059">lipid</z:chebi> fraction with current counter distribution and furthermore fractionated onto HPLC <z:chebi fb="48" ids="30563">silica</z:chebi> column </plain></SENT>
<SENT sid="5" pm="."><plain>The results show: 1. cardiolipin is present in the blood of end-stage renal patients </plain></SENT>
<SENT sid="6" pm="."><plain>2 </plain></SENT>
<SENT sid="7" pm="."><plain>Blood <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> specifically inhibits PAF-induced aggregation in washed rabbit platelets </plain></SENT>
<SENT sid="8" pm="."><plain>3 </plain></SENT>
<SENT sid="9" pm="."><plain>Scatchard plot analysis of PAF binding, in the presence of unlabelled PAF and in the presence of <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>, shows that rabbit platelets possess two different types of binding sites </plain></SENT>
<SENT sid="10" pm="."><plain>One of which is saturable and of high affinity, kD = 0.103 +/- 0.03 nM (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, n = 3) with 337 +/- 94 binding sites per platelet for PAF and kD = 0.087 +/- 0.02 nM with 371 +/- 92.7 binding sites per platelet for <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> while the other one has almost infinite binding capacity </plain></SENT>
<SENT sid="11" pm="."><plain>4 </plain></SENT>
<SENT sid="12" pm="."><plain>Blood <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> competes [3H]PAF binding in rabbit platelets </plain></SENT>
<SENT sid="13" pm="."><plain>This work shows that <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> exists in the blood of end-stage renal patients and specifically inhibits PAF-induced aggregation as well as PAF binding in rabbit platelets </plain></SENT>
<SENT sid="14" pm="."><plain>The possible implication of the biological actions of <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> in the anticardiolipin-<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is also discussed </plain></SENT>
</text></document>